Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their longestablished efficacy, generic availability, and favorable reimbursement positioning. However, branded therapies, including Brintellix (Lundbeck’s vortioxetine) and Spravato (Johnson & Johnson Innovative Medicine’s esketamine), are important treatment alternatives, particularly for treatment-resistant depression (TRD). Given the highly genericized nature of the MDD therapy market, the differences in the availability of drugs in the EU5, the heterogeneity of the MDD patient population, and patients’ varied responses to treatment, the prescribing pattern of EU5 psychiatrists and GPs / internists can vary. Understanding the decision points and challenges that physicians face when treating MDD is paramount for marketers of current therapies and developers of emerging therapies to assess the opportunities for drug development in this highly prevalent indication in Europe.
Questions answered
- What are the drivers and constraints influencing physicians’ treatment decisions for MDD?
- How are patients being treated in various lines of therapy, and what is the patient share of individual therapies?
- What percentage of drug-treated MDD patients are partial responders, and what percentage are treatment-resistant? What is the most common course of action for partial responders and TRD patients?
- To what extent is polypharmacy used for MDD in different lines of therapy in the EU5?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
Geography: France, Germany, Italy, Spain, United Kingdom
Primary research: Survey of 125 EU5 psychiatrists and 125 EU5 GPs / internists (25 psychiatrists and 25 GPs / internists per country
Key drugs: Brintellix, Spravato, Reagila, Rxulti, SSRIs, SNRIs
Key analyses
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
